Beta-amyloid peptides undergo regulated co-secretion with neuropeptide andcatecholamine neurotransmitters

Peptides

Volumn 46, Issue , 2013, Pages 126-135

  Toneff, Thomas ^a   Funkelstein, Lydiane ^a   Mosier, Charles ^a   Abagyan, Armen ^a   Ziegler, Michael ^b   Hook, Vivian ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Catecholamines; Dense core secretory vesicles; Neuropeptides; Neurotransmitters; Regulated secretion; Amyloid

Indexed keywords

ADRENALIN; AMYLOID BETA PROTEIN; BETA SECRETASE; CATECHOLAMINE; DOPAMINE; ENKEPHALIN; FORSKOLIN; GALANIN; GAMMA SECRETASE; NEUROPEPTIDE; NEUROTRANSMITTER; NICOTINE; NORADRENALIN;

ARTICLE; CATECHOLAMINE RELEASE; CELL ORGANELLE; CHROMAFFIN CELL; DEPOLARIZATION; ENZYME PURIFICATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; SECRETORY VESICLE;

AMYLOID PRECURSOR PROTEIN; APP; AΒ; BOVINE SERUM ALBUMIN; BSA; CATECHOLAMINES; DCSV; DENSE CORE SECRETORY VESICLES; NEUROPEPTIDE Y; NEUROPEPTIDES; NEUROTRANSMITTERS; NPY; PBS; PHOSPHATE-BUFFERED SALINE; REGULATED SECRETION; Β-AMYLOID;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CATECHOLAMINES; CATTLE; CELLS, CULTURED; CHROMAFFIN CELLS; COLFORSIN; CYCLIC AMP; DOPAMINE; ENKEPHALINS; EPINEPHRINE; GALANIN; GANGLIONIC STIMULANTS; HUMANS; NEUROBLASTOMA; NEURONS; NEUROPEPTIDE Y; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; NICOTINE; NOREPINEPHRINE; PEPTIDE FRAGMENTS; SECRETORY VESICLES;

EID: 84885009957     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2013.04.020     Document Type: Article

References (67)

1. Bark SJ, Wegrzyn J, Taupenot L, Ziegler M, O'Connor D, Ma Q, et al. The pro-tein architecture of human secretory vesicles reveals differential regulation ofsignaling molecule secretion by protein kinases. PLoS ONE 2012;7:e41134.
2. Benilova I, Karran E, De Strooper B. The toxic A oligomer and Alzheimer'sdisease: an emperor in need of clothes. Nat Neurosci 2012;15:349-57.
3. Bero AW, Yan P, Roh JE, Cirrito JR, Stewart FR, Raichle ME, et al. Neuronalactivity regulates the regional vulnerability to amyloid-beta deposition. Nature2011;14:750-8.
4. Burgess TL, Kelly RB. Constitutive and regulated secretion of proteins. Annu RevCell Biol 1987;3:243-93.
5. Carmichael SW, Winkler H. The adrenal chromaffin cell. Sci Am 1985;253:40-9.
6. Crews L, Masliah E. Molecular mechanisms of neurodegeneration inAlzheimer's disase. Hum Mol Genet 2010;19:R12-20.
7. Diaz-Vera J, Morales YG, Hernandez-Fernaud JR, Camacho M, Montesinos MS,Calegari F, et al. Chromogranin B gene ablation reduces the catecholminecargo and decelerates exocytosis in chromaffin secretory vesicles. J Neurosci2010;30:950-7.
8. Duboff B, Feany M, Götz J. Why size matters-balancing mitochondrial dynam-ics in Alzheimer's disease. Trends Neurosci 2013 Apr 11.
9. Efthimiopoulos S, Vassilacopoulou D, Rippellino JA, Tezapsidis N, Robakis NK.Cholinergic agonists stimulate secretion of soluble full-length amyloid precur-sor protein in neuroendocrine cells. Proc Natl Acad Sci USA 1996;93:8046-50.
10. Fawver JN, Duong KT, Wise-Scira O, Petrofes Chapa R, Schall HE, CoskunerO, et al. Probing and trapping a sensitive conformation: amyloid-fibrils,oligomers, and dimers. J Alzheimers Dis 2012;32:197-215.
11. Fujita-Yoshigaki J. Divergence and convergence in regulated exocytosis: thecharacteristics of cAMP-dependent enzyme secretion of parotid salivary acinarcells. Cell Signal 1998;10:371-5.
12. Funkelstein L, Lu WD, Koch B, Mosier C, Toneff T, Taupenot L, et al. Humancathepsin V protease participates in production of enkephalin and NPY neu-ropeptide neurotransmitters. J Biol Chem 2012;287:15232-41.
13. Gandy S, Martins RN, Buxbaum J. Molecular and cellular basis for anti-amyloidtherapy in Alzheimer's disease. Alzheimer Dis Assoc Disord 2003;17:259-66.
14. Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al.especially apolipoprotein E4, increases the oligomerization of amyloid pep-tide. J Neurosci 2012;32:15181-92.
15. Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J, et al.Inhibition of cathepsin B reduces amyloid production in regulated secretoryvesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate-eta-secretase of Alzheimer's disease. Biol Chem 2005;386:931-40.
16. Hook V, Funkelstein L, Lu D, Bark S, Wegrzyn J, Hwang SR. Proteases forprocessing proneuropeptides into peptide neurotransmitters and hormones.Annu Rev Pharmacol Toxicol 2008;48:393-423.
17. Hook V, Kindy M, Reinheckel T, Peters C, Hook G. Genetic cathepsin B deficiencyreduces beta-amyloid in transgenic mice expressing human wild-type amyloidprecursor protein. Biochem Biophys Res Commun 2009;386:284-8.
18. Huang Y, Mucke L. Alzheimer mechansims and therapeutic strategies. Cell2012;16:1204-22.
19. Jolly-Tornetta C, Gao ZY, Lee VM, Wolf BA. Regulation of amyloid precursorprotein secretion by glutamate receptors in human Ntera 2 neurons. J Biol Chem1998;272:140015-21.
20. Kamenetz F, Tomita T, Hsieh H, Seabrok G, Borchelt D, Iwatsubo T, et al. APPprocessing and synaptic function. Neuron 2003;37:925-37.
21. Kandelepas PC, Vassar R. Identification and biology of beta-secretase. J Neu-rochem 2012;1:55-61.
22. Kim SH, Fraser PE, Westaway D, St George-Hyslop PH, Ehrlich M, Gandy S.Group II metabotropic glutamate receptor stimulation triggers production andrelease of Alzheimer's amyloid beta42 from isolated intact nerve terminals. JNeurosci 2010;30:3870-5.
23. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin,Aph-1, and Pen-2. Proc Natl Acad Sci USA 2003;100:6382-7.
24. Kimberly WT, Xia W, Rahmati T, Wolfe MS, Selkoe DJ. The transmembraneaspartates in presenilin 1 and 2 are obligatory for gamma-secretase activityand amyloid beta-protein generation. J Biol Chem 2000;275:3173-8.
25. Kindy M, Yu J, Zhu H, El-Amouri SS, Hook V, Hook GR. Deletion of the cathepsinB gene improves memory deficits in a transgenic Alzheimer's disease mousemodel expressing APP containing the wild-type beta-secretase site sequence.J Alzheimers Dis 2012;29:827-40.
26. Klein DM, Felsenstein KM, Brenneman DE, Cathepsins B. L differentially regulateamyloid precursor protein processing. J Pharmacol Exp Ther 2009;328:813-21.
27. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, et al. ADAM10is the physiologically relevant, constitutive alpha-secretase of the amyloid pre-cursor protein in primary neurons. EMBO J 2010;29:3020-32.
28. Lauritzen I, Pardossi-Piquard R, Bauer C, Brigham E, Abraham JD, Ranaldi S,et al. secretase-derived C-terminal fragment of APP, C99, but not A, isa key contributor to early intraneuronal lesions in triple-transgenic mousehippocampus. J Neurosci 2012;32:16243-55.
29. Lee SF, Shah S, Li H, Yu C, Han W, Yu G. Mammalian APH-1 interacts withpresenilin and nicastrin and is required for intramembrane proteolysis ofamyloid-beta precursor protein and Notch. J Biol Chem 2002;277:45013-9.
30. Lilja AM, Röjdner J, Mustafiz T, Thomé CM, Storelli E, Gonzalez D, et al. Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice followingmodulation of brain amyloid-levels. PLoS ONE 2013;8:e58752.
31. Lodish H, Berk A, Matsudaira P, Kaiser CA, Krieger M, Scott MP, et al. Molecularcell biology. fifth ed. New York: W. H. Freeman and Company; 2004. p. 701-42.
32. Luo WJ, Wang H, Li H, Kim BS, Shah S, Lee HJ, et al. PEN-2 and APH-1 coordinatelyregulate proteolytic processing of presenilin 1. J Biol Chem 2003;278:7850-4.
33. Mahata SK, Mahata M, Wen G, Wong WB, Mahapatra NR, Hamilton BA, et al.The catecholamine release-inhibitory catestatin fragment of chromogranin A:naturally occurring human variants with different potencies for multiple chro-maffin cell nicotinic cholinergic responses. Mol Pharmacol 2004;66:180-191.
34. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damageand mitochondrial dysfunction in Alzheimer's disease: implications for earlyintervention and therapeutics. Biochim Biophys Acta 2011;1812:1359-70.
35. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals and amyloid-beta inAlzheimer's disease. Int J Exp Pathol 2005;86:147-59.
36. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Sol-uble pool of Abeta amyloid as a determinant of severity of neurodegenerationin Alzheimer's disease. Ann Neurol 1999;46:860-6.
37. Nitsch RJ, Farber S, Growdon JH, Wurtman RJ. Release of amyloid beta-proteinprecursor derivatives by electrical depolarization of rat hippocampal slices.Proc Natl Acad Sci USA 1993;90:5191-3.
38. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer's amy-loid precursor derivatives by activation of muscarinic acetylcholine receptors.Science 1992;258:304-7.
39. Njus D, Kelley PM, Harnadek GJ. The chromaffin vesicle: a model secretoryorganelle. Physiologist 1985;28:235-41.
40. O'Connor DT, Mahata S, Mahata M, Jiang Q, Hook V, Taupenot L. Primary cultureof bovine chromaffin cells. Nat Protoc 2007;2:1248-53.
41. Park Y, Kim KT. Short-term plasticity of small synaptic vesicle (SSV) and largedense core vesicle (LDCV) exocytosis. Cellular signaling 2009;21:1465-70.
42. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, et al. Adisintegrin-metalloproteinase prevents amyloid plaque formation and hip-pocampal defects in an Alzheimer disease mouse model. J Clin Invest2004;113:1456-64.
43. Randall AD, Witton J, Booth C, Hynes-Allen A, Brown JT. The functional neu-rophysiology of the amyloid precursor protein (APP) processing pathway.Neuropharmacology 2010;59:243-67.
44. Roberts BR, Ryan TM, Bush AI, Masters CL, Duce JA. The role of met-allobiology and amyloid-peptides in Alzheimer's disease. J Neurochem2012;120:149-66.
45. Rosen RF, Tomidokoro Y, Ghiso J, Walker LC. SDS-PAGE/immunoblot detectionof A multimers in human cortical tissue homogenates using antigen-epitoperetrieval. J Vis Exp 2010;38 http://www.jove.com/details/php?id= 1916
46. Rustay NR, Wrenn CC, Kinney JW, Holmes A, Bailey KR, Sullivan TL, et al.Galanin impairs performance on learning and memory tasks: findings fromgalanin transgenic and GAL-R1 knockout mice. Neuropeptides 2005;39:239-43.
47. Sala F, Nistri A, Criado M. Nicotinic acetylcholine receptors of adrenal chromaf-fin cells. Acta Physiol 2008;192:203-12.
48. Schmitt U, Hiemke C, Fahrenholz F, Schroeder A. Over-expression of two dif-ferent forms of the alpha-secretase ADAM10 affects learning and memory inmice. Behav Brain Res 2006;175:278-84.
49. Seamon KB, Daly JW, Metzger H, de Souza NJ, Reden J. Structure-activity rela-tionships for activation of adenylate cyclase by the diterpene forskolin and itsderivatives. J Med Chem 1983;26:436-9.
50. Seino S, Takahashi H, Fujimoto W, Shibasaki T. Roles of cAMP signalling ininsulin granule exocytosis. Diabetes Obes Metab 2009;4:180-8.
51. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev2001;81:741-66.
52. Siegel GJ, Agranoff BS, Albers RW, Fisher SK, Uhler MD. Basic neurochemistry.sixth ed. Philadelphia: Lippincott-Raven; 1999. p. 191-400.
53. Sisodia SS. Alzheimer's disease: perspective for the new millennium. J ClinInvest 1999;104:1169-70.
54. Smith AD, Winkler H. A simple method for the isolation of adrenal chromaffingranules on a large scale. Biochem J 1967;103:480-2.
55. Squire L, Berg D, Bloom F, Du Lac S, Ghosh A, Spitzer N. Fundamental neuro-science. third ed. Amsterdam: Elsevier; 2008. p. 41-271.
56. Steiner RA, Hohmann JG, Holmes A, Wrenn CC, Cadd G, Juréus A, et al. Galanintransgenic mice display cognitive and neurochemical deficits characteristic ofAlzheimer's disease. Proc Natl Acad Sci USA 2001;98:4184-9.
57. Tezapsidis N, Li HC, Ripellino JA, Efthimiopoulos S, Vassilacopoulou D, Samba-murti K, et al. Release of nontransmembrane full-length Alzheimer's amyloidprecursor protein from the lumenar surface of chromaffin granule membranes.Biochemistry 1998;37:1274-82.
58. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, et al. Endo-proteolysis of presenilin 1 and accumulation of processed derivatives in vivo.Neuron 1996;17:181-90.
59. Vassar R, Kovacs DM, Uan R, Wong PC. The beta-secretase enzyme BACE inhealth and Alzheimer's disease: regulation, cell biology, function, and thera-peutic potential. J Neurosci 2009;29:12787-94.
60. Vassilacopoulou D, Ripellino JA, Tezapsidis N, Hook VYH, Robakis NK. Full-length and truncated Alzheimer amyloid precursors in chromaffin granules:solubilization of membrane amyloid precursor is mediated by an enzymaticmechanism. J Neurochem 1995;64:2140-6.
61. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization ofamyloid beta-protein begins intracellularly in cells derived from human brain.Biochemistry 2000;39:10831-9.
62. Wegrzyn J, Lee J, Neveu JM, Lane WS, Hook V. Proteomics of neuroen-docrine secretory vesicles reveal distinct functional systems for biosynthesisand exocytosis of peptide hormones and neurotransmitters. J Proteome Res2007;6:1652-65.
63. Wegrzyn JL, Bark SJ, Funkelstein L, Mosier CA, Yap A, Kazemi-Esfarjani P, et al.Proteomics of dense core secretory vesicles reveal distinct protein categoriesfor secretion of neuroeffectors for cell-cell communication. J Proteome Res2010;9:5002-24.
64. Westmark CJ. What's hAPPening at synapses? The role of amyloid protein precursor and amyloid in neurological disorders. Mol Psychiatry2013;18:425-34.
65. Yasothornsrikul S, Toneff T, Hwang SR, Hook VYH. Arginine and lysineaminopeptidase activities in chromaffin granules of bovine adrenalmedulla: relevance to prohormone processing. J Neurochem 1998;70:153-63.
66. Yasothornsrikul S, Greenbaum D, Medzihradszky KF, Toneff T, Bundey R, MillerR, et al. Cathepsin L in secretory vesicles functions as a prohormone-processingenzyme for production of the enkephalin peptide neurotransmitter. Proc NatlAcad Sci U S A 2003;100:9590-5.
67. Ziegler MG, Kennedy B, Elayan H. A sensitive radioenzymatic assay forepinephrine forming enzymes. Life Sci 1988;43:2117-22.